224 related articles for article (PubMed ID: 11433417)
1. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
[TBL] [Abstract][Full Text] [Related]
2. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
3. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
4. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
5. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
Cuellar DC; Rhee J; Kyprianou N
Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
[TBL] [Abstract][Full Text] [Related]
6. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
7. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Benning CM; Kyprianou N
Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715
[TBL] [Abstract][Full Text] [Related]
8. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
9. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion.
Keledjian K; Garrison JB; Kyprianou N
J Cell Biochem; 2005 Feb; 94(2):374-88. PubMed ID: 15526277
[TBL] [Abstract][Full Text] [Related]
10. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component.
Anglin IE; Glassman DT; Kyprianou N
Prostate Cancer Prostatic Dis; 2002; 5(2):88-95. PubMed ID: 12496995
[TBL] [Abstract][Full Text] [Related]
11. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting.
Borre M; Nerstrøm B; Overgaard J
Clin Cancer Res; 2000 May; 6(5):1882-90. PubMed ID: 10815911
[TBL] [Abstract][Full Text] [Related]
12. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
13. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Sutton MT; Yingling M; Vyas A; Atiemo H; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2006 Aug; 66(11):1194-202. PubMed ID: 16652387
[TBL] [Abstract][Full Text] [Related]
14. Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells.
Pan SL; Guh JH; Huang YW; Chern JW; Chou JY; Teng CM
J Urol; 2003 Feb; 169(2):724-9. PubMed ID: 12544352
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of angiogenesis with expression of vascular endothelial growth factor and its receptors in lung carcinoma].
Zhang G; Zhao M; Xu M; Yang Y; Wang M; Yang C
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Feb; 25(2):89-93. PubMed ID: 11953105
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines.
Xu K; Wang X; Ling M; Wong Y
Chin Med J (Engl); 2003 Nov; 116(11):1673-7. PubMed ID: 14642133
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Jackson MW; Bentel JM; Tilley WD
J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis.
Fujiwaki R; Hata K; Iida K; Maede Y; Miyazaki K
Anticancer Res; 2000; 20(2B):1317-22. PubMed ID: 10810442
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells.
Ferrer FA; Miller LJ; Andrawis RI; Kurtzman SH; Albertsen PC; Laudone VP; Kreutzer DL
J Urol; 1997 Jun; 157(6):2329-33. PubMed ID: 9146665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]